Ameriprise’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-31,410
| Closed | -$118K | – | 3920 |
|
|
2024
Q1 | $118K | Sell |
31,410
-1,042,745
| -97% | -$6.11M | ﹤0.01% | 3763 |
|
|
2023
Q4 | $10.5M | Buy |
1,074,155
+971,764
| +949% | +$7.95M | ﹤0.01% | 1739 |
|
|
2023
Q3 | $855K | Buy |
102,391
+20,948
| +26% | +$239K | ﹤0.01% | 3210 |
|
|
2023
Q2 | $1.08M | Sell |
81,443
-1,391,749
| -94% | -$16.9M | ﹤0.01% | 3136 |
|
|
2023
Q1 | $17.1M | Sell |
1,473,192
-142,435
| -9% | -$1.42M | 0.01% | 1386 |
|
|
2022
Q4 | $13.2M | Buy |
1,615,627
+1,579,844
| +4,415% | +$13.6M | ﹤0.01% | 1512 |
|
|
2022
Q3 | $208K | Buy |
+35,783
| New | +$205K | ﹤0.01% | 3694 |
|
|
2022
Q2 | – | Sell |
-28,649
| Closed | -$260K | – | 3965 |
|
|
2022
Q1 | $260K | Sell |
28,649
-2,474,038
| -99% | -$28.5M | ﹤0.01% | 3688 |
|
|
2021
Q4 | $51.2M | Buy |
2,502,687
+280,209
| +13% | +$6.76M | 0.01% | 834 |
|
|
2021
Q3 | $56.8M | Buy |
2,222,478
+2,311
| +0.1% | +$68.5K | 0.02% | 712 |
|
|
2021
Q2 | $77.6M | Buy |
2,220,167
+471,044
| +27% | +$13.7M | 0.02% | 610 |
|
|
2021
Q1 | $58.3M | Sell |
1,749,123
-581,377
| -25% | -$20.3M | 0.02% | 712 |
|
|
2020
Q4 | $60.5M | Buy |
2,330,500
+2,146,953
| +1,170% | +$36.5M | 0.02% | 655 |
|
|
2020
Q3 | $1.81M | Sell |
183,547
-888,531
| -83% | -$5.12M | ﹤0.01% | 2721 |
|
|
2020
Q2 | $3.7M | Buy |
1,072,078
+629,869
| +142% | +$2.14M | ﹤0.01% | 2274 |
|
|
2020
Q1 | $1.35M | Sell |
442,209
-577,395
| -57% | -$2.36M | ﹤0.01% | 2680 |
|
|
2019
Q4 | $5.24M | Buy |
1,019,604
+651,911
| +177% | +$3.31M | ﹤0.01% | 2209 |
|
|
2019
Q3 | $1.9M | Buy |
367,693
+61,237
| +20% | +$343K | ﹤0.01% | 2718 |
|
|
2019
Q2 | $1.85M | Buy |
306,456
+16,768
| +6% | +$118K | ﹤0.01% | 2797 |
|
|
2019
Q1 | $2.09M | Buy |
289,688
+173,366
| +149% | +$1.25M | ﹤0.01% | 2719 |
|
|
2018
Q4 | $862K | Buy |
116,322
+103,330
| +795% | +$655K | ﹤0.01% | 3003 |
|
|
2018
Q3 | $76K | Sell |
12,992
-3,000
| -19% | -$12.9K | ﹤0.01% | 3640 |
|
|
2018
Q2 | $56K | Buy |
15,992
+20
| +0.1% | +$55 | ﹤0.01% | 3600 |
|
|
2018
Q1 | $33K | Hold |
15,972
| – | – | ﹤0.01% | 3600 |
|
|
2017
Q4 | $42K | Hold |
15,972
| – | – | ﹤0.01% | 3601 |
|
|
2017
Q3 | $84K | Sell |
15,972
-409,025
| -96% | -$1.76M | ﹤0.01% | 3615 |
|
|
2017
Q2 | $1.51M | Sell |
424,997
-47,938
| -10% | -$193K | ﹤0.01% | 2743 |
|
|
2017
Q1 | $2.44M | Buy |
472,935
+930
| +0.2% | +$4.55K | ﹤0.01% | 2489 |
|
|
2016
Q4 | $1.79M | Buy |
+472,005
| New | +$3.43M | ﹤0.01% | 2683 |
|
|
2014
Q4 | – | Sell |
-13,884
| Closed | -$68K | – | 4179 |
|
|
2014
Q3 | $68K | Sell |
13,884
-842
| -6% | -$4.4K | ﹤0.01% | 3853 |
|
|
2014
Q2 | $91K | Sell |
14,726
-8,325
| -36% | -$41.7K | ﹤0.01% | 3623 |
|
|
2014
Q1 | $123K | Sell |
23,051
-11,702
| -34% | -$74K | ﹤0.01% | 3427 |
|
|
2013
Q4 | $182K | Buy |
34,753
+10,379
| +43% | +$47.7K | ﹤0.01% | 3180 |
|
|
2013
Q3 | $134K | Buy |
24,374
+192
| +0.8% | +$666 | ﹤0.01% | 3346 |
|
|
2013
Q2 | $61K | Buy |
+24,182
| New | +$60.2K | ﹤0.01% | 3607 |
|
Other funds holding PACB
AIM
MA
EDRH
NAMA
JSP
Ameriprise's PACB Position: Q2 2024 in Review
Ameriprise sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 31,410 shares — an estimated $118K sold.
Ameriprise first reported a position in PACB in Q2 2013 and held it in 35 quarters. The position peaked at $77.6M in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.
- Ameriprise reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
- Ameriprise sold 31,410 Pacific Biosciences shares in Q2 2024, an estimated $118K.
- Ameriprise first reported a position in Pacific Biosciences in Q2 2013 and held it in 35 quarters.
- Ameriprise's Pacific Biosciences position peaked at $77.6M in Q2 2021.
- 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.
Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.